Berlin, Germany

Rheumatologische Schwerpunktpraxis

Arthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Guselkumab

Filgotinib

Galapagos

Janssen (J&J Innovative Medicine)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Rheumatologische Schwerpunktpraxis | Berlin, Germany

Site insights

Work at this site?

Active trials

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

Trial sponsors